Latest News for: gsk

Edit

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, ...

Nasdaq Globe Newswire 24 Apr 2026
The Germany Anemia Treatment Market is set to reach USD 1.05 billion by 2034, growing at a CAGR of 6.84% from USD 581.344 million in 2025 ... .
Edit

Transaction notification (Form 6-K) (GSK plc)

Public Technologies 24 Apr 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account ... About GSK ... Find out more at www.gsk.com ... GSK plc ... behalf of GSK plc.
Edit

Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest

Invezz 24 Apr 2026
The FTSE 100 Index pulled back this week as the US-Iran war continued and after the UK published a hot consumer inflation report ... Similarly, GlaxoSmithKline, popularly known as GSK, has formed a double-top-like pattern, signaling potential retreat.
Edit

Current Report by Foreign Issuer (Form 6-K) (GSK plc)

Public Technologies 23 Apr 2026
GSK plc published this content on April 23, 2026, and is solely responsible ...
Edit

FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings

Invezz 23 Apr 2026
The FTSE 100 Index pulled back for three consecutive days as companies exposed to the ongoing US-Iran war slipped and as the UK published a strong inflation report. It also dropped as market participants waited for the upcoming UK corporate earnings.
Edit

Transaction in own shares (Form 6-K) (GSK plc)

Public Technologies 22 Apr 2026
GSK plc published this content on April 22, 2026, and is solely responsible ...
Edit

Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

PR Newswire 22 Apr 2026
Prolyl tRNA synthetase inhibitors as a new antimalarial project led by MMV, GSK (GlaxoSmithKline Investigacion y Desarrollo, S.L.), and the University of Tokyo ... (GSK).
Edit

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Nasdaq Globe Newswire 20 Apr 2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq. ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business ... .
Edit

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK

Caledonian Record 20 Apr 2026
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash ....
Edit

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations (Form 8-K) (AnaptysBio Inc)

Public Technologies 20 Apr 2026
Manages GSK and Vanda Financial Collaborations... Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders.
Edit

Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma (Form 6-K) (GSK plc)

Public Technologies 20 Apr 2026
GSK plc ... GSK plc (LSE/NYSE ... Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said ... GSK in oncology ... About GSK ... Find out more at www.gsk.com. GSK enquiries ... [5] GSK press release issued 9 December 2024 ... GSK plc ... behalf of GSK plc.
×